Form 4 for CNSP CNS Pharmaceuticals, Inc.

Accepted 2024-02-06 00:00:00 ET · period of report 2024-02-01 · accession 0001683168-24-000705 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-02-06	2024-02-01	CNSP	Climaco John M	CEO, Dir	P - Purchase	$0.3	+166.7K	215.7K	+340%	+$50.0K
DM	2024-02-06	2024-02-01	CNSP	Climaco John M	CEO, Dir	A - Grant	—	+333.3K	393.5K	+554%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common stock	2024-02-01	P	A	166,666	$0.3	215,676	D	—	—	(F1) The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.
2	Derivative	Series A Warrant to purchase common stock	2024-02-01	A	A	166,666	—	226,867	D	$0.3 · 2024-02-01 to 2029-02-01	166,666 Common Stock	(F1) The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.
3	Derivative	Series B Warrant to purchase common stock	2024-02-01	A	A	166,666	—	393,533	D	$0.3 · 2024-02-01 to 2025-10-01	166,666 Common Stock	(F1) The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.